Education · Tier 5

· Last Reviewed May 12, 2026· PSI Editorial Board· Independent

What's the Difference Between Compounded and FDA-Approved Peptides?

The honest map of how compounded and FDA-approved peptides differ in regulatory oversight, evidence base, quality assurance, and what physician due diligence requires.

FDA-approved peptides have undergone FDA pre-market review including Phase 3 trial evidence.

Compounded peptides do not receive FDA pre-market approval but route through 503A pharmacies or 503B outsourcing facilities under the FDA Compounding Quality Act.

Both require a physician prescription.

The regulatory frameworks differ in important ways.

Phase 3

FDA-Approved Evidence

Phase 3 trial evidence and FDA pre-market review for indication, safety, and efficacy

503A/B

Compounding Framework

FDA Compounding Quality Act defines 503A patient-specific and 503B bulk outsourcing categories

USP 797/800

Pharmacy Standards

USP Chapter 797 sterile compounding and USP 800 hazardous drug handling compliance

PCAB

Accreditation Standard

Pharmacy Compounding Accreditation Board verifies operational quality benchmarks

Quick Answer

FDA-approved peptides have undergone FDA pre-market review including Phase 3 trial evidence. Compounded peptides do not receive FDA pre-market approval but route through licensed pharmacies under the FDA Compounding Quality Act.

FDA-approved peptides include Semaglutide as Wegovy and Ozempic. The list also covers Tirzepatide as Zepbound and Mounjaro. Other examples include Liraglutide as Saxenda and Victoza, Teriparatide as Forteo, and Romosozumab as Evenity. Each carries FDA-reviewed prescribing information.

Compounded peptides route through 503A pharmacies or 503B outsourcing facilities. The 503A category compounds for individual patient prescriptions under state pharmacy board oversight. The 503B category compounds in bulk under FDA registration and inspection. The FDA Compounding Quality Act governs this framework. Quality assurance depends on pharmacy practices including third-party testing, USP Chapter 797 sterile compounding, USP Chapter 800 hazardous drug handling, and PCAB accreditation.

Recent FDA scrutiny on compounded GLP-1 receptor agonists has highlighted pharmacy quality variability. Salt-form variants of FDA-approved molecules face specific FDA enforcement. Physician due diligence on compounded peptide prescriptions is essential.

The FDA-approved pathway is preferred when an FDA-approved peptide matches the patient indication. Compounded pathways become appropriate during FDA shortage list inclusion, insurance coverage limitations, or absence of FDA-approved peptide for the indication. AMA Code of Medical Ethics 1.1.5 governs off-label and informed consent framework.

For specific guidance, see Do I Need a Doctor for Peptides and How Physicians Recommend Peptides. Also see Red Flags in Peptide Prescribing and Finding a Peptide Doctor.

FDA-approved peptide injectables include Wegovy and Ozempic for semaglutide, plus Zepbound and Mounjaro for tirzepatide. The list also includes Saxenda and Victoza for liraglutide, Forteo for teriparatide, Tymlos for abaloparatide, Evenity for romosozumab, Sermorelin, and Tesamorelin as Egrifta. Each carries FDA-reviewed prescribing information specifying indication, contraindications, dosing, monitoring, and warnings. Compounded peptides are different. Under the FDA Compounding Quality Act, 503A pharmacies compound for individual patient prescriptions with state pharmacy board oversight. Bulk compounding happens through 503B outsourcing facilities under FDA registration and inspection. Neither category receives FDA pre-market approval for the compounded product. Quality assurance depends on pharmacy practices including third-party testing, USP Chapter 797 sterile compounding compliance, USP Chapter 800 hazardous drug handling, and PCAB accreditation. Recent FDA scrutiny on compounded GLP-1 receptor agonists has highlighted pharmacy quality variability. Patients exploring compounded peptide pathways should consult your physician to verify pharmacy quality assurance before any prescription.

WHICH PATHWAY?

At a Glance: Compounded vs FDA-Approved Peptides

Patient Scenario	Subtitle	Animal Evidence	Human Evidence	Pathway Approach
Adult seeking FDA-approved weight management peptide	FDA prescribing information pathway	—	Strong	Wegovy or Zepbound per FDA labeling with primary care or obesity medicine specialty
Adult seeking FDA-approved type 2 diabetes peptide	FDA prescribing information pathway	—	Strong	Ozempic or Mounjaro per ADA Standards of Care with primary care or endocrinology
Adult seeking compounded GLP-1 during FDA shortage list inclusion	503A or 503B pharmacy with quality verification	—	Moderate	Compounded semaglutide or tirzepatide only when on FDA shortage list and pharmacy quality verified
Adult seeking compounded peptide outside FDA shortage list scope	Higher physician due diligence threshold	—	Moderate	Compounded preparation outside shortage context requires deeper pharmacy quality verification
Adult considering compounded peptide salt-form variant	FDA scrutiny on salt-form compounded GLP-1 applies	—	Limited	Salt-form variants of FDA-approved molecules face FDA enforcement; verify pharmacy compliance
Patient with FDA-approved alternative available	FDA-approved pathway preferred per AMA Code	—	Strong	Compounded pathway is not the default when FDA-approved option exists for the indication
Patient with insurance coverage limitation on FDA-approved	Compounded with documented quality and informed consent	—	Moderate	Compounded pathway viable with verified pharmacy quality and AMA Code 1.1.5 informed consent
Patient with no FDA-approved peptide for indication	Compounded or off-label FDA-approved with specialty coordination	—	Moderate	Specialty coordination strengthens compounded or off-label decisions per AMA Code framework

Six Things You Need to Know About Compounded vs FDA-Approved Peptides

This page covers the regulatory and quality differences between FDA-approved and compounded peptides. The framework spans six sections. Section one explains the four regulatory categories. Section two covers FDA pre-market review and what the approval process establishes. Section three deep-dives the 503A vs 503B compounding pharmacy framework. Section four addresses recent FDA scrutiny on compounded GLP-1 receptor agonists. Section five covers physician due diligence for compounded peptide prescriptions. Section six addresses when compounded is appropriate and when FDA-approved should be preferred.

Four Regulatory Categories Govern Peptide Products in the United States

FDA-approved drugs, compounded preparations, research-grade chemicals, and DSHEA supplements are four legally distinct categories with different oversight, evidence, and prescription requirements.

FDA-approved peptides have undergone FDA pre-market review. The FDA evaluates safety, efficacy, manufacturing quality, and labeling before approval. Examples include Wegovy and Ozempic (semaglutide NDAs 215256 and 209637), Zepbound and Mounjaro (tirzepatide NDAs 217806 and 215866), Saxenda and Victoza (liraglutide), Forteo (teriparatide NDA 021318), Tymlos (abaloparatide), Evenity (romosozumab NDA 761062 with cardiovascular boxed warning), Sermorelin, and Tesamorelin as Egrifta. Compounded peptides operate under the FDA Compounding Quality Act of 2013. 503A pharmacies compound for individual patient prescriptions under state pharmacy board oversight. 503B outsourcing facilities compound in bulk under FDA registration and inspection. Research-grade peptides labeled not for human use are sold outside the FDA framework for laboratory research purposes. DSHEA dietary supplements like collagen peptides and creatine are categorically separate from therapeutic peptide injectables. The categorical distinctions are not marketing language. They are legal categories under federal drug law. Patients should consult your physician about which regulatory category applies to any peptide under consideration.

FDA Pre-Market Review Establishes Indication, Safety, and Efficacy

FDA approval requires Phase 3 trial evidence demonstrating safety and efficacy for specific indications. The approval process establishes the prescribing information that physicians follow.

The FDA pre-market review process for drug approval requires sponsors to submit New Drug Applications (NDAs) including manufacturing data, preclinical safety, and Phase 1 through Phase 3 clinical trial evidence. FDA-approved peptide approvals reference specific Phase 3 trial data. Wegovy STEP trials demonstrated approximately 15 percent body weight reduction over 68 weeks. Wegovy SELECT 2023 demonstrated 20 percent MACE reduction in obesity without diabetes. Ozempic SUSTAIN-6 demonstrated cardiovascular benefit in type 2 diabetes. Zepbound SURMOUNT-1 demonstrated approximately 21 percent weight reduction. Mounjaro SURPASS demonstrated type 2 diabetes efficacy. Forteo Phase 3 demonstrated approximately 65 percent vertebral fracture reduction. Tymlos ACTIVE Phase 3 demonstrated approximately 86 percent vertebral fracture reduction. Evenity FRAME demonstrated 73 percent vertebral fracture reduction. The FDA prescribing information for each approved peptide specifies the approved indication, contraindications, warnings, dosing, monitoring requirements, and adverse event profile. Physicians prescribing FDA-approved peptides within the indication follow established standards. Off-label prescribing of FDA-approved peptides is legal under AMA Code of Medical Ethics 1.1.5 with documented informed consent.

503A Pharmacies vs 503B Outsourcing Facilities Have Distinct Frameworks

The FDA Compounding Quality Act defines two compounding pharmacy categories with different oversight. 503A is patient-specific compounding under state pharmacy board oversight. 503B is bulk compounding under FDA registration and inspection.

503A pharmacies compound for individual patient prescriptions. The pharmacy receives the prescription from a licensed physician for a specific patient. State pharmacy boards license, inspect, and regulate 503A operations. The FDA does not pre-approve 503A compounded products. Physician due diligence on 503A compounded peptide prescriptions includes verifying state license, accreditation status, third-party purity and potency testing, sterility certification, USP Chapter 797 sterile compounding standards compliance, and USP Chapter 800 hazardous drug handling compliance. 503B outsourcing facilities compound in bulk under FDA registration and inspection. The 503B category was created after the 2012 New England Compounding Center meningitis outbreak that killed 64 patients to provide FDA oversight for bulk-compounded sterile products. The FDA registers 503B facilities directly, conducts inspections, and tracks adverse event reports. 503B compounded products may be used by physicians for office stock or specific patient prescriptions. Physician due diligence on 503B compounded peptide products includes verifying FDA registration status, inspection history, and adverse event reporting compliance. Neither 503A nor 503B compounded products receive FDA pre-market approval for the compounded product itself. Discuss with your physician about pharmacy verification before any compounded prescription.

FDA Scrutiny on Compounded GLP-1 Peptides Has Expanded Since 2023

The FDA has issued guidance and pursued enforcement against substandard compounded GLP-1 receptor agonist products. Salt-form variants of FDA-approved molecules face specific scrutiny.

Compounded semaglutide and compounded tirzepatide products have been the subject of FDA guidance documents and enforcement actions since 2023. The FDA Drug Shortage list framework permits compounding of products on the shortage list under specific conditions. When Ozempic, Wegovy, Mounjaro, and Zepbound were added to the FDA shortage list during the period of acute supply constraint, compounding pharmacies could produce compounded versions for patients. As the supply situation has evolved, the FDA has taken these products off and on the shortage list with shifting compliance windows. The FDA has issued specific guidance addressing salt-form variants of semaglutide and tirzepatide that differ from the FDA-approved active pharmaceutical ingredient. Salt-form variants face FDA scrutiny because the variant is not the FDA-approved molecule. The FDA has pursued enforcement against facilities producing substandard compounded products including issues with potency, identity, and sterility. Patients pursuing compounded GLP-1 therapy should work with physicians who verify pharmacy FDA registration status (for 503B), state license status (for 503A), recent inspection history, third-party potency and purity testing, USP standards compliance, and adverse event reporting practices. The compounded GLP-1 pathway is legitimate when the pharmacy meets the regulatory standard. The pathway becomes problematic when the pharmacy operates outside the framework. Specialty coordination strengthens complex compounded GLP-1 decisions.

Physician Due Diligence for Compounded Peptides Requires Multiple Verification Steps

Compounded peptide prescriptions require physician verification across pharmacy accreditation, third-party testing, USP standards compliance, and adverse event protocols. The due diligence is the quality gate.

Physician due diligence on compounded peptide prescriptions includes multiple verification steps. State pharmacy board license verification confirms the pharmacy is licensed in its state of operation. For 503B outsourcing facilities, FDA registration verification confirms the facility is FDA-registered. PCAB accreditation verification confirms the pharmacy has voluntarily met the Pharmacy Compounding Accreditation Board operational quality standard. Third-party purity and potency testing verification confirms the pharmacy uses independent laboratories for product quality testing. USP Chapter 797 sterile compounding compliance verification confirms the pharmacy follows the standard for compounding sterile preparations. USP Chapter 800 hazardous drug handling compliance verification confirms the pharmacy follows the standard for hazardous drug handling. Adverse event reporting verification confirms the pharmacy maintains adverse event tracking and reporting protocols. Documented informed consent per AMA Code of Medical Ethics 1.1.5 addresses the compounded status and quality assurance basis distinct from FDA-approved alternatives. Specialty coordination strengthens compounded peptide decisions across primary care and specialty practice including endocrinology, weight medicine, and rheumatology. Patients should consult your physician about which compounded preparation pathway is appropriate and what pharmacy quality verification supports that pathway.

FDA-Approved Pathway Is Preferred When the Indication Match Exists

When an FDA-approved peptide matches the patient indication, the FDA-approved pathway is preferred over the compounded pathway. Compounded becomes appropriate when FDA-approved options have limitations.

The default framework prioritizes FDA-approved peptide prescribing when an FDA-approved peptide matches the patient indication. Wegovy and Saxenda for chronic weight management. Ozempic and Victoza for type 2 diabetes with cardiovascular benefit. Zepbound and Mounjaro for chronic weight management and type 2 diabetes. Forteo, Tymlos, and Evenity for high fracture risk osteoporosis. The FDA-approved pathway carries the strongest evidence and regulatory foundation. Compounded peptide prescribing is appropriate in specific scenarios. Scenario one is FDA shortage list inclusion where supply of the FDA-approved product is constrained. Scenario two is insurance coverage limitation where the patient cannot access the FDA-approved product through their insurance plan. Scenario three is the absence of an FDA-approved peptide for the patient indication where compounded peptides may be the only option. Scenario four is patient-specific factors like dose adjustment or formulation that the FDA-approved product does not support. In all scenarios, the physician documents the rationale for the compounded pathway including the FDA-approved alternative considered, the reason for the compounded pathway, the pharmacy quality verification, and the informed consent per AMA Code of Medical Ethics. Specialty coordination strengthens complex decisions. Discuss with your physician about which pathway fits your clinical context and indication match.

Four regulatory categories: FDA-approved vs compounded vs research-grade vs DSHEA supplement

The four categories under US federal drug law and what each requires

FDA-approved peptides have completed FDA pre-market review under the Federal Food Drug and Cosmetic Act. The approval process evaluates safety, efficacy, manufacturing quality, and labeling. Examples include Wegovy and Ozempic (semaglutide NDAs 215256 and 209637), Zepbound and Mounjaro (tirzepatide NDAs 217806 and 215866), Saxenda and Victoza (liraglutide), Forteo (teriparatide NDA 021318), Tymlos (abaloparatide), Evenity (romosozumab NDA 761062), Sermorelin, and Tesamorelin as Egrifta. Each carries FDA-reviewed prescribing information specifying indication, contraindications, dosing, monitoring, warnings, and adverse event profile.

Compounded peptides operate under the FDA Compounding Quality Act of 2013. 503A pharmacies compound for individual patient prescriptions under state pharmacy board oversight. 503B outsourcing facilities compound in bulk under FDA registration and inspection. Both require a physician prescription. Neither category receives FDA pre-market approval for the compounded product itself. The regulatory oversight model differs by category. Quality assurance depends on pharmacy practices.

Research-grade peptides labeled not for human use are sold by suppliers operating outside FDA and state pharmacy board frameworks. The labels are legal disclaimers separating research chemicals from therapeutic drugs. Research-grade products do not undergo FDA pre-market approval. Quality, purity, sterility, and adverse event reporting are not guaranteed. Physicians do not generally prescribe through research suppliers. Patient self-sourcing for therapeutic use operates outside validated clinical practice.

DSHEA dietary supplements like collagen peptides, creatine, and amino acid supplements operate under the Dietary Supplement Health and Education Act of 1994. DSHEA supplements do not require a prescription, but they cannot make therapeutic claims, treat disease, or be marketed as drug equivalents. The DSHEA category is genuinely over-the-counter for non-therapeutic products. Therapeutic peptide injectables are NOT DSHEA supplements. The categorical distinction is the legal gate between OTC supplements and prescription-only therapeutic peptides.

FDA pre-market review vs compounded approval framework

What FDA approval establishes and what the compounded pathway does and does not include

FDA approval for a prescription drug requires the sponsor to submit a New Drug Application including manufacturing data, preclinical safety, and Phase 1 through Phase 3 clinical trial evidence. The FDA reviews safety, efficacy, manufacturing quality, and labeling before approval. For peptides, the Phase 3 trial evidence base is substantial. Wegovy STEP trials demonstrated approximately 15 percent body weight reduction over 68 weeks. Wegovy SELECT 2023 demonstrated 20 percent MACE reduction in obesity without diabetes. Ozempic SUSTAIN-6 demonstrated cardiovascular benefit in type 2 diabetes. Zepbound SURMOUNT-1 demonstrated approximately 21 percent weight reduction. Forteo Phase 3 demonstrated approximately 65 percent vertebral fracture reduction. Evenity FRAME demonstrated 73 percent vertebral fracture reduction.

Compounded peptide approval does not exist as a category. The FDA Compounding Quality Act provides a regulatory framework for the compounding pharmacy operations, but does not approve the compounded product itself for pre-market safety and efficacy in the way FDA drug approval does. 503A and 503B compounded products are not equivalent to FDA-approved drugs. They are different regulatory categories serving different patient access needs. The framework is appropriate when patients need access to a compounded preparation under specific circumstances, but the regulatory standard is structurally different from FDA pre-market approval.

FDA prescribing information is specific to the FDA-approved product. The prescribing information includes the approved indication, contraindications, warnings, dosing, monitoring requirements, drug interactions, adverse event profile, and special populations. Physicians prescribing FDA-approved peptides within indication follow this prescribing information. Compounded peptide products do not have FDA-reviewed prescribing information. Physician judgment, AMA Code of Medical Ethics 1.1.5 informed consent framework, and pharmacy quality assurance are the operating standards for compounded peptide prescriptions.

503A patient-specific compounding vs 503B bulk outsourcing facility framework

How the two compounding pharmacy categories differ in oversight, scope, and physician due diligence

503B outsourcing facilities compound in bulk under FDA registration and inspection. The 503B category was established by the Drug Quality and Security Act of 2013 (which created the Compounding Quality Act framework) after the 2012 New England Compounding Center meningitis outbreak that killed 64 patients and sickened hundreds more. The 503B framework provides FDA-level oversight for bulk-compounded sterile products. The FDA registers 503B facilities directly, conducts inspections, and tracks adverse event reports. 503B compounded products may be used by physicians for office stock or specific patient prescriptions.

Physician due diligence on compounded peptide prescriptions includes verification across multiple dimensions. For 503A: state pharmacy board license verification, PCAB accreditation status, third-party purity and potency testing, sterility certification, USP Chapter 797 sterile compounding compliance, USP Chapter 800 hazardous drug handling compliance, and adverse event reporting practices. For 503B: FDA registration verification, FDA inspection history, third-party testing practices, and adverse event reporting compliance. Discuss with your physician about pharmacy verification before any compounded prescription.

Neither 503A nor 503B compounded products receive FDA pre-market approval for the compounded product itself. The framework regulates the compounding pharmacy operation, not the specific compounded preparation. This is the structural difference from FDA-approved drugs. The framework is appropriate when patients need access to compounded preparations under specific circumstances. The framework is not equivalent to FDA pre-market approval and should not be marketed as such.

FDA scrutiny on compounded GLP-1 receptor agonists and salt-form variants

How the FDA Drug Shortage list and salt-form enforcement shape compounded GLP-1 access

The FDA Drug Shortage list framework permits compounding of products on the shortage list under specific conditions. When Ozempic, Wegovy, Mounjaro, and Zepbound were added to the FDA shortage list during periods of acute supply constraint in 2022 and 2023, compounding pharmacies could produce compounded versions for patients. The FDA has periodically removed and reinstated these products on the shortage list as supply has evolved. Each transition includes a compliance window for pharmacies to wind down compounding of the affected product. Patients pursuing compounded GLP-1 therapy should consult your physician about current FDA shortage list status for the specific product under consideration.

Salt-form variants of FDA-approved molecules face specific FDA scrutiny. The FDA has issued guidance addressing semaglutide salt-form variants like semaglutide sodium and semaglutide acetate that differ from the FDA-approved active pharmaceutical ingredient. Salt-form variants are not the FDA-approved molecule. The FDA has pursued enforcement against facilities producing salt-form variant compounded products and has clarified that salt-form variants do not qualify under the FDA Drug Shortage list compounding framework. Patients should verify with the prescribing physician that any compounded GLP-1 product uses the FDA-approved molecule and not a salt-form variant.

FDA enforcement against substandard compounded products has expanded since 2023. Issues identified include potency variation (compounded products containing more or less of the active ingredient than labeled), identity mismatches (compounded products containing different molecules than labeled), and sterility failures (compounded sterile preparations failing sterility testing). The FDA has issued warning letters, pursued seizure actions, and worked with state pharmacy boards on enforcement. Patients pursuing compounded GLP-1 therapy should work with physicians who verify pharmacy FDA registration status (for 503B), state license status (for 503A), recent inspection history, third-party potency and purity testing, USP standards compliance, and adverse event reporting practices.

Research Suggests

Direction

The regulatory framework for peptide therapy has four legally distinct categories with different oversight, evidence base, and physician due diligence requirements.

FDA-approved peptides have the strongest evidence and regulatory foundation through FDA pre-market review including Phase 3 trial evidence. Compounded peptides route through 503A pharmacies (state pharmacy board oversight) or 503B outsourcing facilities (FDA registration and inspection) under the FDA Compounding Quality Act. Neither compounded category receives FDA pre-market approval for the compounded product itself. Research-grade peptides operate outside FDA and state pharmacy board frameworks. DSHEA dietary supplements are categorically separate from therapeutic peptide injectables. The categorical distinctions are the structural framework for evidence-graded peptide practice.

Strongest evidence

FDA-approved peptide prescribing within indication has the strongest evidence and regulatory foundation across all peptide therapy pathways.

FDA-approved peptides have Phase 3 trial evidence demonstrating safety and efficacy for specific indications. Wegovy SELECT 2023 demonstrated 20 percent MACE reduction in obesity without diabetes. Ozempic SUSTAIN-6 demonstrated cardiovascular benefit in type 2 diabetes. Zepbound SURMOUNT-1 demonstrated approximately 21 percent weight reduction. Forteo Phase 3 demonstrated approximately 65 percent vertebral fracture reduction. Tymlos ACTIVE Phase 3 demonstrated approximately 86 percent vertebral fracture reduction. Evenity FRAME demonstrated 73 percent vertebral fracture reduction. The FDA prescribing information specifies indication, contraindications, dosing, monitoring, and adverse event profile. Physicians prescribing within indication follow established standards. The FDA-approved pathway should be the default when an FDA-approved peptide matches the patient indication.

Limitations

Compounded peptide prescribing requires physician due diligence on pharmacy quality assurance and informed consent specific to the compounded status.

Compounded peptides do not receive FDA pre-market approval for the compounded product. Quality assurance depends on pharmacy practices. Recent FDA scrutiny on compounded GLP-1 receptor agonists has highlighted pharmacy quality variability. Salt-form variants of FDA-approved molecules face FDA enforcement and do not qualify under the shortage list framework. Insurance coverage for compounded peptides is typically limited or absent. Physician due diligence is essential including state pharmacy board license verification, FDA registration verification for 503B, PCAB accreditation, third-party testing, USP Chapter 797 and 800 compliance, and adverse event reporting practices. Patients should consult your physician about pharmacy quality verification.

Assessment

FDA-approved is preferred when indication matches. Compounded is acceptable with verified pharmacy quality and documented informed consent. Research-grade is outside validated practice.

PSI's reading: the FDA-approved pathway is preferred when an FDA-approved peptide matches the patient indication. Compounded peptide pathways become appropriate in specific scenarios including FDA shortage list inclusion, insurance coverage limitation, absence of FDA-approved peptide for the indication, or patient-specific factors that the FDA-approved product does not support. Compounded prescribing requires verified pharmacy quality assurance and documented informed consent per AMA Code of Medical Ethics 1.1.5. Research-grade peptide self-sourcing operates outside validated clinical practice and is not a substitute for physician-prescribed FDA-approved or compounded therapy. Specialty coordination strengthens complex decisions across primary care and specialty practice. Anyone framing compounded peptides as equivalent to FDA-approved peptides or framing research-grade peptides as a legitimate physician-free pathway is making a claim that does not hold under the regulatory framework.

How to Approach Your Decision

Limitations and Caveats

FDA-approved peptides carry the strongest evidence and regulatory foundation. Phase 3 trial evidence with FDA-reviewed prescribing information establishes the prescribing standard.
Compounded peptides do not receive FDA pre-market approval for the compounded product. The FDA Compounding Quality Act regulates the compounding pharmacy operation, not the specific compounded preparation.
Quality assurance for compounded products depends on pharmacy practices. Physician due diligence on state license, FDA registration for 503B, PCAB accreditation, third-party testing, and USP compliance is essential.
Recent FDA scrutiny on compounded GLP-1 receptor agonists has expanded since 2023. Salt-form variants of FDA-approved molecules face specific FDA enforcement and do not qualify under shortage list compounding.
Insurance coverage for compounded peptides is typically limited or absent. FDA-approved peptides for FDA-approved indications generally have better coverage with prior authorization.
Off-label use of FDA-approved peptides requires documented informed consent. AMA Code of Medical Ethics 1.1.5 governs the framework with documented risk-benefit assessment.
Specialty coordination strengthens complex compounded peptide decisions. Multi-specialty review per AMA Code framework supports patients with multiple comorbidities or complex indications.
The FDA-approved pathway should be the default when indication match exists. Compounded becomes appropriate during FDA shortage list inclusion, insurance limitation, absence of FDA-approved option, or patient-specific factors.

What's Marketed vs What's Studied

7 common claims, corrected.

“Compounded peptides are FDA-approved because they come from a pharmacy.”

Compounded peptides do NOT receive FDA pre-market approval for the compounded product. The FDA Compounding Quality Act regulates the compounding pharmacy operation (503A state pharmacy board oversight or 503B FDA registration). The framework governs the pharmacy, not the specific compounded preparation. Compounded peptide products are not equivalent to FDA-approved drugs like Wegovy or Ozempic.

“Compounded peptides have no FDA oversight at all.”

Compounded peptides operate under the FDA Compounding Quality Act of 2013. 503B outsourcing facilities are FDA-registered and FDA-inspected. 503A pharmacies operate under state pharmacy board oversight with state license requirements. The FDA has issued guidance and pursued enforcement against substandard compounded products. The oversight framework is different from FDA pre-market approval but it is not absent.

“All compounding pharmacies are equivalent in quality and oversight.”

Compounding pharmacy quality varies significantly. PCAB accreditation is voluntary and provides an independent operational quality benchmark. USP Chapter 797 sterile compounding compliance and USP Chapter 800 hazardous drug handling compliance are key standards. Third-party purity and potency testing practices vary by pharmacy. Adverse event reporting and FDA inspection history (for 503B) vary by facility. Physician due diligence on pharmacy quality is essential before any compounded prescription.

“Compounded semaglutide is the same as FDA-approved Wegovy or Ozempic.”

Compounded semaglutide is NOT the same as FDA-approved Wegovy or Ozempic. FDA-approved products have undergone FDA pre-market review including Phase 3 trial evidence (Wegovy SELECT, Ozempic SUSTAIN-6) and have FDA-reviewed prescribing information. Compounded semaglutide products do not receive FDA pre-market approval, do not have FDA-reviewed prescribing information, and quality varies by compounding pharmacy. Recent FDA scrutiny on compounded GLP-1 receptor agonists confirms the regulatory and quality distinction.

“Salt-form variants of FDA-approved molecules are equivalent to the FDA-approved drug.”

Salt-form variants like semaglutide sodium and semaglutide acetate are NOT the FDA-approved molecule. The FDA has issued specific guidance addressing salt-form variants and has pursued enforcement against facilities producing salt-form variant compounded products. Salt-form variants do not qualify under the FDA Drug Shortage list compounding framework. Patients should verify that any compounded GLP-1 product uses the FDA-approved active pharmaceutical ingredient, not a salt-form variant.

“If a peptide is on the FDA shortage list, compounding is always permitted.”

The FDA Drug Shortage list framework permits compounding under specific conditions, but the FDA periodically removes and reinstates products as supply evolves. Each transition includes a compliance window for pharmacies to wind down compounding. Patients should verify current FDA shortage list status for the specific product with the prescribing physician. The shortage list status is not permanent and can change as supply situations evolve.

“Compounded peptides are always cheaper and therefore better value.”

Price is not a measure of quality or regulatory standing. Compounded peptides are typically not covered by insurance, which can mean lower out-of-pocket cost than uninsured FDA-approved products but higher cost than insured FDA-approved options with prior authorization. FDA-approved Wegovy, Ozempic, Zepbound, and Mounjaro may have manufacturer savings programs (NovoCare, LillyDirect) that reduce out-of-pocket costs. Total cost calculation should include insurance coverage, manufacturer programs, and quality assurance, not list price alone.

Common Questions

What is the main difference between FDA-approved and compounded peptides?

FDA-approved peptides have undergone FDA pre-market review including Phase 3 trial evidence demonstrating safety and efficacy for specific indications. The FDA reviews safety, efficacy, manufacturing quality, and labeling before approval. Compounded peptides do not receive FDA pre-market approval for the compounded product but operate under the FDA Compounding Quality Act framework regulating the compounding pharmacy operation. Both require a physician prescription. The regulatory frameworks differ in oversight depth and pre-market review.

Are compounded peptides FDA-approved?

No. Compounded peptide products do not receive FDA pre-market approval. The FDA Compounding Quality Act regulates the compounding pharmacy operation. 503A pharmacies operate under state pharmacy board oversight. 503B outsourcing facilities operate under FDA registration and inspection. Neither category receives FDA pre-market approval for the specific compounded preparation itself. This is the structural distinction from FDA-approved drugs like Wegovy or Ozempic.

What is a 503A compounding pharmacy?

A 503A pharmacy compounds for individual patient prescriptions under state pharmacy board oversight. The pharmacy receives the prescription from a licensed physician for a specific patient. State pharmacy boards license, inspect, and regulate 503A operations. The FDA does not pre-approve 503A compounded products. State pharmacy board oversight varies by state including Texas, Florida, California, and others with established frameworks. PCAB accreditation is voluntary but provides an independent operational quality benchmark.

What is a 503B outsourcing facility?

A 503B outsourcing facility compounds in bulk under FDA registration and inspection. The 503B category was established by the Drug Quality and Security Act of 2013 after the 2012 New England Compounding Center meningitis outbreak that killed 64 patients. The FDA registers 503B facilities directly, conducts inspections, and tracks adverse event reports. 503B compounded products may be used by physicians for office stock or specific patient prescriptions.

What's the difference between 503A and 503B compounding?

503A is patient-specific compounding under state pharmacy board oversight. The pharmacy compounds for individual patient prescriptions one at a time. 503B is bulk compounding under FDA registration and inspection. The facility compounds in bulk and the FDA oversees registration and inspection directly. 503A regulates the pharmacy operation through state law. 503B regulates the facility through federal FDA framework. Neither category receives FDA pre-market approval for the compounded product itself.

Why has the FDA scrutinized compounded GLP-1 peptides?

The FDA has issued guidance and pursued enforcement against substandard compounded GLP-1 receptor agonist products since 2023. Issues identified include potency variation, identity mismatches, sterility failures, and salt-form variants that differ from FDA-approved molecules. The FDA has issued warning letters, pursued seizure actions, and worked with state pharmacy boards on enforcement. Patients pursuing compounded GLP-1 therapy should work with physicians who verify pharmacy quality assurance.

What are salt-form variants and why do they matter for compounded peptides?

Salt-form variants are chemical modifications of the FDA-approved molecule like semaglutide sodium or semaglutide acetate that differ from the FDA-approved active pharmaceutical ingredient. The FDA has issued specific guidance addressing salt-form variants and has clarified that salt-form variants do not qualify under the FDA Drug Shortage list compounding framework. Patients should verify that any compounded GLP-1 product uses the FDA-approved molecule, not a salt-form variant. Salt-form variants face FDA enforcement.

What does the FDA shortage list framework allow for compounding?

The FDA Drug Shortage list framework permits compounding of products on the shortage list under specific conditions. When Ozempic, Wegovy, Mounjaro, and Zepbound were added to the shortage list during acute supply constraint in 2022 and 2023, compounding pharmacies could produce compounded versions for patients. The FDA periodically removes and reinstates products as supply evolves. Each transition includes a compliance window. Patients should verify current shortage list status with the prescribing physician.

Is compounded semaglutide as effective as Wegovy?

Compounded semaglutide products do not undergo the same Phase 3 trial evidence demonstrating effectiveness as FDA-approved Wegovy. Wegovy SELECT 2023 demonstrated 20 percent MACE reduction in obesity without diabetes through Phase 3 trial evidence. Compounded semaglutide preparations vary in quality, potency, and identity by compounding pharmacy. Quality assurance depends on pharmacy practices. The FDA-approved product carries the strongest evidence base. Discuss with your physician whether FDA-approved Wegovy is accessible for your specific clinical context.

What is PCAB accreditation?

PCAB stands for Pharmacy Compounding Accreditation Board. PCAB accreditation is a voluntary accreditation program that establishes operational quality standards for compounding pharmacies. PCAB-accredited pharmacies have met independent benchmarks for quality assurance, sterility, documentation, and operational practices. PCAB accreditation is one factor in physician due diligence on compounded peptide prescriptions but is not a substitute for state pharmacy board license or FDA registration verification.

What are USP Chapter 797 and 800?

USP Chapter 797 is the United States Pharmacopeia standard for sterile compounding. It establishes requirements for sterile compounded preparations including environmental controls, personnel training, beyond-use dating, and quality assurance. USP Chapter 800 establishes standards for hazardous drug handling including personal protective equipment, engineering controls, and personnel training. Compounding pharmacies should comply with both standards for sterile peptide compounding. Physician due diligence includes verifying USP 797 and 800 compliance.

How can I verify a compounding pharmacy is legitimate?

For 503A pharmacies, verify state pharmacy board license status through the state board portal, PCAB accreditation status (voluntary but useful indicator), and third-party testing practices. For 503B outsourcing facilities, verify FDA registration status through the FDA registration database and FDA inspection history. For both categories, verify USP Chapter 797 and 800 compliance and adverse event reporting practices. Discuss with your physician about pharmacy verification before any compounded prescription.

Is insurance coverage available for compounded peptides?

Insurance coverage for compounded peptides is typically limited or absent. FDA-approved peptides like Wegovy, Ozempic, Zepbound, and Mounjaro for FDA-approved indications generally have better coverage with prior authorization. Manufacturer savings programs like NovoCare for Wegovy and Ozempic, and LillyDirect for Zepbound and Mounjaro, may reduce out-of-pocket costs. Compounded peptide products are typically paid out of pocket. Verify coverage with your insurance plan before pursuing any pathway.

When is compounded appropriate vs FDA-approved?

The FDA-approved pathway is preferred when an FDA-approved peptide matches the patient indication. Compounded becomes appropriate in specific scenarios: FDA shortage list inclusion where supply of the FDA-approved product is constrained, insurance coverage limitation where the FDA-approved product is inaccessible, absence of an FDA-approved peptide for the patient indication, or patient-specific factors like dose adjustment that the FDA-approved product does not support. Specialty coordination strengthens these decisions.

Can my physician prescribe compounded peptides?

Yes. Licensed physicians can write prescriptions for compounded peptides routed through 503A pharmacies or 503B outsourcing facilities. The physician evaluates the clinical context, considers FDA-approved alternatives first, verifies pharmacy quality assurance, and documents informed consent per AMA Code of Medical Ethics 1.1.5 specifying the compounded status. Discuss with your physician about which pathway fits your clinical context and indication match.

What if the FDA-approved version of my peptide is on the FDA shortage list?

When an FDA-approved peptide is on the FDA shortage list, the framework permits compounding under specific conditions. The 503A pharmacy or 503B outsourcing facility can compound versions of the shortage list product for patients. The FDA periodically removes and reinstates products as supply evolves. When a product is removed from the shortage list, a compliance window applies for pharmacies to wind down compounding. Verify current shortage list status with the prescribing physician for any specific product.

What red flags should I watch for with compounded peptide offers?

Red flags include direct-to-consumer marketing without physician prescription requirement, claims that compounded products are equivalent to FDA-approved (they are not), salt-form variants marketed as semaglutide or tirzepatide, absence of state pharmacy board license verification (for 503A) or FDA registration verification (for 503B), absence of PCAB accreditation, no third-party testing information, and absence of adverse event reporting protocols. See [Red Flags in Peptide Prescribing](/education/red-flags-in-peptide-prescribing) for the full framework.

Where do research-grade peptides fit in this framework?

Research-grade peptides labeled not for human use operate OUTSIDE the FDA Compounding Quality Act framework entirely. Research suppliers are not 503A pharmacies. Research suppliers are not 503B outsourcing facilities. The product labels are not therapeutic drug labels. Physicians do not generally prescribe through research suppliers. Patient self-sourcing from research suppliers does not create a compounding pathway and does not produce a prescription. The framework is structurally different. Patients considering peptide therapy should pursue FDA-approved or compounded pharmacy pathways through a physician.

Sourcing Checklist

Verify FDA-approved indication match before pursuing compounded pathway.
If an FDA-approved peptide matches the patient indication (Wegovy for chronic weight management, Ozempic for type 2 diabetes, Forteo for high fracture risk osteoporosis, etc.), the FDA-approved pathway is preferred. Compounded becomes appropriate only when FDA-approved options have specific limitations.
For 503A compounded pathway, verify state pharmacy board license is active and unrestricted.
State pharmacy board portals provide online license verification. Confirm the pharmacy's primary state license is active, unrestricted, and current. Discuss with your physician about state license verification before any compounded prescription.
For 503B compounded pathway, verify FDA registration status through the FDA database.
The FDA maintains a registration database for 503B outsourcing facilities at fda.gov. Confirm the facility is FDA-registered and review recent inspection history. Discuss with your physician about FDA registration verification before any 503B compounded prescription.
Verify PCAB accreditation status as one indicator of operational quality.
PCAB accreditation is voluntary but provides an independent operational quality benchmark. PCAB-accredited pharmacies have met operational standards for sterility, documentation, and quality assurance. PCAB accreditation is one factor in physician due diligence, not the sole criterion.
Confirm USP Chapter 797 sterile compounding and USP Chapter 800 hazardous drug handling compliance.
USP Chapter 797 establishes the standard for sterile compounded preparations. USP Chapter 800 establishes the standard for hazardous drug handling. Both are foundational for sterile peptide compounding. Discuss with your physician about USP standards verification with the prescribing pharmacy.
Verify third-party purity and potency testing practices.
Independent third-party testing of compounded products for purity, potency, and identity is a quality assurance indicator. Discuss with your physician about whether the prescribing pharmacy uses third-party testing and what testing schedule applies to compounded peptide preparations.
For compounded GLP-1 receptor agonists, verify the FDA-approved molecule is used (not a salt-form variant).
The FDA has issued guidance addressing semaglutide and tirzepatide salt-form variants that differ from the FDA-approved active pharmaceutical ingredient. Salt-form variants face FDA enforcement. Confirm with the prescribing physician that any compounded GLP-1 product uses the FDA-approved molecule, not a salt-form variant.
For compounded GLP-1 receptor agonists, verify current FDA shortage list status.
The FDA periodically adds and removes products from the Drug Shortage list. Compounding of shortage list products is permitted under specific conditions. Each transition includes a compliance window. Verify with the prescribing physician about current shortage list status before any compounded GLP-1 prescription.
Confirm informed consent documentation per AMA Code of Medical Ethics 1.1.5.
AMA Code 1.1.5 requires documented risk-benefit assessment, alternatives considered (including FDA-approved options), and patient understanding for off-label and compounded prescribing decisions. AMA Code 2.1.1 establishes the informed consent framework. Patients can request copies of consent documentation.

Regulatory Context

The FDA Compounding Quality Act framework and FDA enforcement on compounded peptides evolves continuously. FDA scrutiny on compounded GLP-1 receptor agonists has expanded since 2024 with guidance addressing salt-form variants of FDA-approved molecules and enforcement actions against substandard compounding facilities. The FDA Drug Shortage list status for Ozempic, Wegovy, Mounjaro, and Zepbound has shifted multiple times as supply situations evolve, with compliance windows for pharmacies to wind down compounding when products are removed from the shortage list. USP Chapter 797 sterile compounding and USP Chapter 800 hazardous drug handling standards continue to refine. State pharmacy board frameworks evolve with state-specific changes to inspection cadences, adverse event reporting requirements, and accreditation expectations. PCAB accreditation standards update periodically. AMA Code of Medical Ethics 1.1.5 and 2.1.1 frameworks for off-label and informed consent remain foundational. PSI tracks regulatory changes and updates this page per the Editorial Standards review cadence. Discuss with your physician for the most current FDA shortage list status and regulatory guidance.

Comparison

Dimension	FDA-Approved	503A Compounded	503B Compounded	Research-Grade
FDA pre-market approval	Yes (NDA reviewed)	No	No	No
Evidence base	Phase 3 trial evidence	No pre-market trial required	No pre-market trial required	No FDA evidence framework
Regulatory oversight	FDA manufacturer + labeling	State pharmacy board	FDA registration + inspection	Outside FDA framework
Prescription required	Yes	Yes - patient-specific	Yes - office or patient	No, but outside FDA framework
FDA-reviewed prescribing info	Yes	No	No	No
Quality assurance source	FDA manufacturer GMP	Pharmacy + USP + PCAB	FDA inspection + USP	Not assured
Insurance coverage	Generally with prior auth	Typically not covered	Typically not covered	Never covered
Salt-form variants	Not applicable	FDA enforcement risk	FDA enforcement risk	Not applicable
PSI recommendation	Preferred when indication matches	Acceptable with verified quality	Acceptable with verified quality	Not recommended outside trials

Who This Applies To

· Adult considering peptide therapy and evaluating FDA-approved versus compounded pathway options.
· Adult with FDA-approved indication match considering Wegovy, Ozempic, Zepbound, Mounjaro, or other FDA-approved peptide.
· Adult considering compounded GLP-1 receptor agonist during FDA shortage list inclusion period.
· Adult considering compounded peptide pathway due to insurance coverage limitation on FDA-approved alternative.
· Adult with no FDA-approved peptide for indication considering compounded or off-label FDA-approved option.
· Adult evaluating compounded peptide salt-form variant claims against FDA enforcement framework.
· Patient verifying 503A pharmacy state license, PCAB accreditation, and USP standards compliance.
· Patient verifying 503B outsourcing facility FDA registration and inspection history.
· Patient comparing FDA-approved Wegovy or Ozempic cost against compounded semaglutide cost with manufacturer programs.
· Patient distinguishing compounded peptide pathway from research-grade peptide self-sourcing.

Verdict

FDA-approved peptides have the strongest evidence and regulatory foundation through FDA pre-market review including Phase 3 trial evidence. The FDA-approved pathway is preferred when an FDA-approved peptide matches the patient indication. Wegovy and Ozempic for weight management and type 2 diabetes. Zepbound and Mounjaro for chronic weight management and type 2 diabetes. Forteo, Tymlos, and Evenity for high fracture risk osteoporosis. Compounded peptides operate under the FDA Compounding Quality Act framework. The 503A category compounds for individual patient prescriptions under state pharmacy board oversight. The 503B category compounds in bulk under FDA registration. Both require a physician prescription. Neither receives FDA pre-market approval for the compounded product. Compounded peptide prescribing is appropriate during FDA shortage list inclusion, insurance coverage limitation, absence of FDA-approved option, or patient-specific factors. Physician due diligence on pharmacy quality is essential. Recent FDA scrutiny on compounded GLP-1 receptor agonists has highlighted pharmacy quality variability. Salt-form variants of FDA-approved molecules face FDA enforcement. Off-label use of FDA-approved peptides is legal under AMA Code of Medical Ethics 1.1.5 with documented informed consent. Research-grade peptide self-sourcing operates outside validated clinical practice and is not a substitute for physician-prescribed therapy. PSI maintains a vetted directory of practitioners with peptide experience operating within validated clinical practice frameworks.

In Plain Terms

FDA-approved peptides have been reviewed by the FDA. The FDA looked at the trial evidence, manufacturing, and labeling before approval. Examples include Wegovy and Ozempic for weight loss and diabetes. Compounded peptides have not been FDA-approved. They are made by special pharmacies under federal and state rules. Both kinds require a doctor prescription. The FDA-approved version is preferred when it matches your situation. Compounded becomes appropriate when the FDA-approved version is hard to access or doesn't exist for your need. Quality of compounded products varies by pharmacy. Recent FDA scrutiny on compounded weight loss peptides shows quality varies. Discuss with your doctor about which pathway fits your situation.

Some peptides are FDA-approved drugs you can get from your doctor with a prescription, like Wegovy or Ozempic. The FDA reviewed the safety and effectiveness before approving them. Other peptides are compounded by specialty pharmacies, which means a pharmacy mixes the medication for you specifically. Compounded peptides still need a doctor prescription, but they have not gone through the same FDA approval. The pharmacy quality matters a lot for compounded products. Some compounded products are good. Some are not. Recent FDA scrutiny on compounded weight loss peptides like compounded semaglutide shows quality varies. Research-grade peptides sold online by suppliers labeled not for human use are a different category entirely. They are not approved or compounded for therapy. They are sold for laboratory research. Using them for therapy is not a legal alternative to a doctor prescription.

For any compounded peptide consideration, physician routing through a verified 503A or 503B pharmacy is the legal gate. PSI maintains a vetted directory of practitioners with peptide experience operating within validated clinical practice frameworks including primary care, telehealth, endocrinology, weight medicine, rheumatology, and other specialties per AMA Code of Medical Ethics 1.1.5 + FDA Compounding Quality Act + USP standards.

Find a verified physician

PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.

Browse the directory Learn about the verification process →

Related Conditions

Related Education

Featured Compounds

Common Contexts

· Adult considering FDA-approved Wegovy, Zepbound, or Saxenda for chronic weight management
· Adult considering FDA-approved Ozempic, Mounjaro, or Victoza for type 2 diabetes
· Adult considering FDA-approved Forteo, Tymlos, or Evenity for high fracture risk osteoporosis
· Adult considering compounded semaglutide or tirzepatide during FDA shortage list inclusion
· Adult evaluating 503A patient-specific compounding pathway with state pharmacy board verification
· Adult evaluating 503B bulk outsourcing facility pathway with FDA registration verification
· Patient verifying PCAB accreditation, USP Chapter 797 and 800 compliance, and third-party testing
· Patient comparing FDA-approved manufacturer savings programs (NovoCare, LillyDirect) against compounded cost
· Patient identifying salt-form variant red flags in compounded GLP-1 receptor agonist offers
· Patient distinguishing research-grade peptide self-sourcing from legitimate compounded pharmacy pathway

Important Context

This page is educational and does not constitute medical advice. The information presented reflects the FDA Compounding Quality Act framework, FDA prescribing information for FDA-approved peptides, USP Chapter 797 and 800 standards, state pharmacy board oversight, FDA guidance on compounded GLP-1 receptor agonists, and AMA Code of Medical Ethics 1.1.5 and 2.1.1 as referenced.

Your physician will evaluate your specific clinical context, FDA-approved indication match, insurance coverage, pharmacy quality assurance for compounded options, and personal preferences when assessing the FDA-approved versus compounded pathway. The framework described here is general and does not substitute for individualized clinical judgment. Specialty coordination strengthens complex decisions.

Educational content only. Discuss with your physician before pursuing any peptide therapy pathway. Compounded peptide pathways require verified pharmacy quality assurance and documented informed consent per AMA Code of Medical Ethics. FDA-approved peptide prescribing within indication follows FDA prescribing information.

Sources and Citations

[1] FDA Prescribing Information: Wegovy (semaglutide) injection 2.4 mg · 2024 · FDA NDA 215256 · Source
[2] FDA Prescribing Information: Ozempic (semaglutide) injection · 2024 · FDA NDA 209637 · Source
[3] FDA Prescribing Information: Zepbound (tirzepatide) injection · 2024 · FDA NDA 217806 · Source
[4] FDA Prescribing Information: Mounjaro (tirzepatide) injection · 2024 · FDA NDA 215866 · Source
[5] FDA Prescribing Information: Forteo (teriparatide) injection · 2020 · FDA NDA 021318 · Source
[6] FDA Prescribing Information: Evenity (romosozumab-aqqg) injection with cardiovascular boxed warning · 2019 · FDA NDA 761062 · Source
[7] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) · New England Journal of Medicine · 2023 · DOI
[8] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · New England Journal of Medicine · 2022 · DOI
[9] AMA Code of Medical Ethics Opinion 1.1.5: Off-label and Investigational Use of Pharmaceuticals · American Medical Association · 2024 · Source
[10] AMA Code of Medical Ethics Opinion 2.1.1: Informed Consent · American Medical Association · 2024 · Source
[11] American Diabetes Association. Standards of Care in Diabetes 2024 · Diabetes Care · 2024 · DOI
[12] Camacho PM, Petak SM, Binkley N, et al. AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update · Endocrine Practice · 2020 · DOI
[13] Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline · Journal of Clinical Endocrinology and Metabolism · 2019 · DOI
[14] FDA Compounding Quality Act framework: 503A pharmacy compounding under state oversight; 503B outsourcing facilities under FDA registration · US Food and Drug Administration · 2023 · Source
[15] FDA Guidance on Compounded Semaglutide and Tirzepatide Products: Salt-Form Variants and Shortage List Framework · US Food and Drug Administration · 2024 · Source
[16] USP Chapter 797 Pharmaceutical Compounding - Sterile Preparations · United States Pharmacopeia · 2023 · Source
[17] USP Chapter 800 Hazardous Drugs - Handling in Healthcare Settings · United States Pharmacopeia · 2023 · Source

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.